[Thoughts on the watch and wait strategy of patients with rectal cancer after neoadjuvant therapy]

Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):230-236. doi: 10.3760/cma.j.cn.441530-20200224-00082.
[Article in Chinese]

Abstract

In 2004, Habr-Gama reported a new group of rectal cancer patients achieving clinical complete response (cCR) after neoadjuvant chemoradiotherapy, who were able to get a satisfactory curative effect after a non-operative watch and wait (W&W) strategy. Since then, W&W has attracted more and more public attention. Although results of accumulating clinical studies have shown that W&W strategy is feasible for treating part of rectal cancer patients, there is still a lack of evidence-based medical evidence. Therefore, the feasibility and safety of the strategy still need further investigation. The main focuses are on the optimized scheme of chemoradiotherapy, the timing and standard to evaluate a cCR, and the shortage of a more precise approach to judging and predicting cCR. Whether a salvage surgery is safe and feasible for local regeneration, the risk of increasing distant metastasis and long-term oncologic and functional outcomes of patients also remain uncertain. Based on the literature and the institute's experience, this paper will elaborate the current development status and existing problems of W&W and look forward to the application prospect and future challenges.

Habr-Gama于2004年率先报道了一组新辅助放化疗后达到临床完全缓解(cCR)直肠癌患者在进行非手术的等待观察(W&W)后,获得满意的疗效。自此,W&W走入人们视线并日益受到关注。虽然越来越多的临床研究结果表明,W&W策略对部分直肠癌患者安全可行,但目前仍然缺乏足够的循证医学证据。因此,对该方案的实施及安全性仍然受到质疑。主要的焦点在于什么是最优化的放化疗方案;cCR的判断时间及判断标准;目前仍然缺乏更精准的手段对cCR进行准确的预测和评估;对局部肿瘤再生后补救手术的实施方案及其安全性;肿瘤远处转移的风险是否会增加;目前尚缺乏患者长期的肿瘤学及功能学随访结果。本文将根据文献并结合本中心的经验,对目前W&W开展现状及存在问题加以阐述,并对其运用前景和未来面临挑战进行展望。.

Keywords: Complete response; Neoadjuvant therapy; Rectal neoplasms; Watch and wait strategy.

MeSH terms

  • Chemoradiotherapy
  • Humans
  • Neoadjuvant Therapy*
  • Neoplasm Recurrence, Local
  • Rectal Neoplasms* / therapy
  • Treatment Outcome
  • Watchful Waiting